Lucy Scientific Discovery, Inc. · OTC:LSDIF
Lucy Scientific Discovery — IPO Roadshow (February 2023)
18 slides from Lucy Scientific Discovery's IPO roadshow presentation, Feb 6, 2023
Slide 1: Company Presentation
Company Presentation CONFIDENTIAL: FEBRUARY 2023 Issuer Free Writing Prospectus Dated February 3, 2023 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration No. 333 - 262296 Related to Preliminary Prospectus dated February 3, 2023
Slide 2: Disclaimer
Disclaimer REGISTRATION STATEMENT Lucy Scientific Discovery Inc. (the “Company”) has filed a registration statement on Form S - 1 (including a preliminary prospectu s) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. The registration state
Slide 3: Key Risks
Key Risks • We have a limited operating history and have not scaled our commercial operations or made significant sales of our products or services, and we have incurred significant losses since our inception . We may continue to incur losses which, together with our limited operating history, makes
Slide 4: Offering Summary
Lucy Scientific Discovery Inc. NASDAQ: LSDI Firm Commitment Initial Public Offering Approximately $8 Million (excluding over - allotment ) Common Shares $ 4 .00 Complete build out and make certain upgrades to manufacturing & research facilities, satisfy certain outstanding liabilities, and for worki
Slide 5: Use of Proceeds & Capitalization
Use of Proceeds & Capitalization Capitalization Table Summary Shares Authorized Shares Outstanding 1 Common Shares Outstanding Fully Diluted % of Potential Fully Diluted Securities Common Shares Unlimited 1 6 , 370,864 1 6 , 370,864 8 4 . 04 % Common Shares 2 2 , 681 , 521 1 3 . 77 % Warrants 3 428,
Slide 6: Seasoned Team
Seasoned Team Chris McElvany President & CEO - Director Dr. Assad J. Kazeminy CSO • Vaporizer technology pioneer and co - founder of one of the world’s best - selling cannabis products, O.penVAPE • Co - founder of Organa Brands - sold to Slang Worldwide (SLGWF) for ~$200mm USD • Multiple patent - ho
Slide 7: Additional Board of Directors
Paul Abramowitz Board Member • 35+ year leader in corporate finance and strategy • Cross - industry executive leadership experience • Experienced in product development process and IP protection Charles Nemeroff Board Member • Chair of the Department of Psychiatry and Behavioral Sciences at the Univ
Slide 8: Company Overview
Company Overview What We Do We are a licensed manufacturer in Canada dedicated to the development of psychotropic and psychedelic treatment therapies addressing mental health and addiction issues. Our Mission Our mission is to become the premier contract manufacturing and research development organi
Slide 9: Investment Highlights
Investment Highlights Large Addressable Market Opportunity A variety of mental health and addiction disorders are promising candidates for psychedelic treatment therapy Regulatory Developments Public support and changing regulations for psychedelic - based therapies Health Canada Licensed Production
Slide 10: Large Addressable Market
Large Addressable Market The global psychedelics market could be worth as much as $11B in revenue by 2027 1 Addressing the Global Mental Health Crisis 2 Addressing the Global Addiction Crisis 2 Suffer from depressive disorders Suffer from anxiety disorders Users of tobacco products Suffer from a sub
Slide 11: Growth Strategy
Growth Strategy Capitalize on activities that: Secure Near Term Revenue • Sign contract manufacturing agreements with key customers • Facilitate and conduct contract psychotropic research • Achieve and maintain compliance excellence Future Growth Drivers • Meet emerging demands with innovative produ
Slide 12: Regulatory Developments
Regulatory Developments Notable academic and clinical research efforts have prompted U.S. and Canadian regulatory bodies to re - evaluate various psychedelic compound classifications 1 FDA granted the Multidisciplinary Association for Psychedelic Studies (MAPS) break through therapy designation to M
Slide 13: Controlled Substance Dealer Licensed Facility
Controlled Substance Dealer Licensed Facility 25,000+ sq. ft. facility in Victoria, British Columbia 100 % Hydroelectric - powered campus, energy efficient design and equipment , compartmentalized production bays, testing and analytics laboratories, and dedicated office space Licensed to produce, re
Slide 14: Production Capabilities
Production Capabilities Lucy is leveraging three key methods of production, with the goal of achieving best - in - class quality and facilitating market penetration through competitive pricing Synthesis Natural Product Extraction Biosynthesis 14
Slide 15: Why Lucy?
We Aim to Be a Premier Manufacturing Organization with Substantial Near - And Long - Term Growth Opportunities in the Emerging Psychotropics Market Large Addressable Market Opportunity Health Canada Licensed Production Facility Innovative Production Technology Regulatory Developments Seasoned Execut
Slide 16: Lucy Scientific Discovery
Lucy Scientific Discovery” LUCYSCIENTIFIC.COM
Slide 17: Natural Product Extraction: Innovative Production Technology
Natural Product Extraction: Innovative Production Technology Lucy - Versus - Provides the capability to quickly scale in order to meet global market needs Minimizes reliance on external suppliers and allows for advanced drug discovery capabilities and pharmaceutical - grade outputs TerraCubeTM not o
Slide 18: Biosynthesis: Leveraging scalable biosynthetic processes for cGMP API production
Genetic pathway for expression of desired API inserted into host cell lines Evaluate, optimize, and advance best candidates via high - throughput screening in microscale bioreactor Scale process to lab - and pilot - scale to produce gram to kilogram cGMP API quantities for research and human clinica
Lucy Scientific Discovery — IPO Roadshow (February 2023) on 6ix